Derma Sciences Inc. (NASDAQ:DSCI) dropped 3.3% on Tuesday . The company traded as low as $4.86 and last traded at $4.95, with a volume of 51,593 shares trading hands. The stock had previously closed at $5.12.

DSCI has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Derma Sciences from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research note on Wednesday, August 3rd. TheStreet upgraded shares of Derma Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, August 9th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Derma Sciences presently has a consensus rating of “Buy” and a consensus target price of $7.35.

The stock’s market cap is $139.26 million. The stock has a 50-day moving average price of $4.50 and a 200-day moving average price of $3.77.

Derma Sciences (NASDAQ:DSCI) last issued its earnings results on Tuesday, August 9th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.16. The firm earned $22.20 million during the quarter, compared to the consensus estimate of $22.40 million. On average, equities research analysts anticipate that Derma Sciences Inc. will post ($0.18) EPS for the current year.

An institutional investor recently raised its position in Derma Sciences stock. Jennison Associates LLC increased its position in Derma Sciences Inc. (NASDAQ:DSCI) by 22.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,407,506 shares of the company’s stock after buying an additional 261,818 shares during the period. Jennison Associates LLC owned about 5.45% of Derma Sciences worth $6,432,000 at the end of the most recent quarter.

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.